DRug Eluting Bbsorbable Metal Scaffold (DREAMS)

Slides:

Advertisements

Similar presentations

Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.

Advertisements

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.

M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.

PCI Unmet Clinical Needs

Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.

Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.

University Hospital La Paz

BY: COURTNEY MEDEIROS BME /30/11 Coronary Stents.

Stenting: Function, Problems, and Procedure. Uses for Stents  Peripheral artery disease (PAD)  Renal vascular hypertension  Hemodialysis access maintenance.

M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.

As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.

The Science Behind Taxus Advanced Angioplasty 2004 Christian Vander Velde, Boston Scientific Europe, Marketing.

BIOSENSORS-CLINICAL UPDATE “LEADERS AND BEYOND” John E Shulze, CTO BIOSENSORS INTERNATIONAL GROUP Jan 29, 2010.

STENTS James Simones. History Balloon Angioplasty introduced in the late 70’s Approximately 30% would close up after Some so severe that the artery would.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

Coronary Stents By: Brian Volpe. Coronary Heart Disease (CHD) is the narrowing and blockage of the coronary arteries that supply the heart with blood.

Need Statement and Need Criteria. Need Statement To prevent the reoccurrence of stenosis in coronary arteries. More specifically, to create a solution.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.

Learning Objectives Drawbacks of traditional POBA

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Are the Culprit Lesions Severely Stenotic? J Am Coll.

LOGO Presenter : S.Mohammad Zargar Supervisor : Dr. Mahdikhani Faculty of Engineering Department of Biomedical Engineering.

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

Bare Metal Stent Self Expandable Stent Balloon Expandable Stent

Self-Expandable Nitinol Coronary Stent

My initial ABSORB experience Assoc. Prof. I. Petrov

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Elena Matteucci Global Product Manager - CID Spa

Bioresorbale Stents Just an Alternative or One-Way Street?

A Novel Abluminal Coated Sirolimus-Eluting Stent as a Treatment Option for Diabetic Patients: Results from an All-Comers Multi-center Study: the En-ABL.

Ron Waksman, MD, FACC, FSCAI

One DES Eluting Two Drugs: Is it Feasible? Robert Falotico, PhD

Paclitaxel Drug-Coated Balloons for De Novo Lesions

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Bioabsorbable DES and Biodegradable Polymers – FDA View

One DES Eluting Two Drugs: Is it Feasible?

Ron Waksman, MD, FACC, FSCAI

DES Bioabsorbable and DCB Technologies

Bioresorbable scaffold: the advent of a new era in percutaneous coronary revascularisation Clinical Data Update Ron Waksman, MD, FACC Director, Cardiovascular.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Present By:- Company Name: Global Market Forecastes Tel: / Web:

Percutaneous coronary intervention (PCI)

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Supervised by: Dr. Paul French, Dr. Mark Murphy, and Dr. Martin Sharp

Nat. Rev. Cardiol. doi: /nrcardio

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Presented at ACC 2003 Late Breaking Clinical Trials

Fig 6.1 Drug released by diffusion

Figure 1 Milestones in coronary angioplasty

(p < 0.05 for paclitaxel angioplasty vs. either control)

Drug-eluting stents for in-stent restenosis

Percutaneous revascularization strategies in a patient with previous coronary artery bypass surgery: Technical and patho-physiological insights Pierfrancesco.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Tornado diagram of one-way deterministic sensitivity analysis.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

American College of Cardiology Presented by Dr. Adnan Kastrati

The American College of Cardiology Presented by Dr. A. Abazid

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Drug-eluting coronary stent market overview

Presentation transcript:

DRug Eluting Bbsorbable Metal Scaffold (DREAMS) Puria Rafsanjani Nejad Shahab shiraghaee

Percutaneous coronary intervention (PCI): Balloon angioplasty Stenting Is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. commonly known as coronary angioplasty or simply angioplasty

Balloon angioplasty Rate of restnosis

Bio-Absorbable Drug-eluting stent Stents Bare metal Stents Drug eluting stents Bio-Absorbable Drug-eluting stent 1.Restenosis and immune response 2.Mechanical weakness Mention the absorbable metal stent trials and … 3.It was an enhancement of prior types

Bio-Absorbable Drug-eluting stent DREAMS is a balloon-expandable, paclitaxel-eluting scaffold on a rapid-exchange delivery system.

Bio-Absorbable Drug-eluting stent

Bio-Absorbable Drug-eluting stent DREAMS was optimized to provide a longer scaffolding time than its predecessor and drug elution for inhibition of cell proliferation. It is made of a magnesium alloy that is gradually absorbed. The absorption process is complete after 9–12 months. The scaffold strut surface is coated with a 1μm matrix of the absorbable polymer carrier polylactic-coglycolic acid and the antiproliferative drug paclitaxel.

Bio-Absorbable Drug-eluting stent

The weakness Late Lumen loss due to plaque presuring the stent!

Heparin coating and getting rid of the paclitaxel Fluoroscopy marking Rotational or laser Atherectomy